Trigeminal neuralgia (TGN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve. Carbamazepine (Tegretol, generics) is the only therapy formally approved for the treatment of TGN in the United States, but its use is limited by safety and tolerability concerns. Therefore, TGN patients may be managed by a variety of off-label medications along their treatment journey, including oxcarbazepine (Supernus’s Oxtellar XR, generics), other antiepileptics, gabapentin (Neurontin, generics), opioid analgesics, and even neuromuscular blocking agents (Allergan’s Botox). However, a substantial portion of TGN patients are treatment refractory, and better treatment options for these patients are needed.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed TGN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed TGN patients?
- How is carbamazepine integrated into the treatment algorithm, given its safety and tolerability disadvantages?
- What proportion of TGN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of TGN patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with TGN?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Pfizer, Allergan
Key drugs: Carbamazepine/ carbamazepine XR, oxcarbazepine, gabapentin, Lyrica, opioid analgesics, Botox, other antiepileptics
Key analysis provided:
- Brand use across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.